OBJECTIVE: The action of noradrenaline on human mesenteric, omental and subcutaneous adipocytes was compared. We also determined whether regional differences in the noradrenaline-effect were linked to variations in adrenoceptor subtype function. DESIGN: The lipolytic effects of different concentrations of noradrenaline (b b1-, b b2-, b b3-and a a2-adrenoceptor agonist), isoprenaline (b b1-, b b2-and b b3-adrenoceptor agonist) and selective b b1-, b b2-and b b3-adrenoceptor agonists (dobutamine, terbutaline and CGP 12177, respectively) were studied in adipocytes isolated from the three adipose tissue regions in the same subject. In addition, the effect of the a a2-adrenoceptor antagonist, yohimbine, was studied on noradrenalineinduced glycerol release. SUBJECTS: Thirteen otherwise healthy obese subjects (nine females, four males). RESULTS: The noradrenaline-induced lipolytic response did not differ between omental and mesenteric adipocytes but was 50% higher than in subcutaneous adipocytes (P`0.05). Furthermore, noradrenaline sensitivity and intrinsic activity (in relation to isoprenaline) were higher in the two visceral fat cells than in the subcutaneous fat cells. The intrinsic activity of noradrenaline increased close to that of isoprenaline when yohimbine was added to the incubation system. Isoprenaline sensitivity was ®ve times higher in the two visceral fat cells than in the subcutaneous fat cells. For CGP 12177, sensitivity and intrinsic activity did not differ between mesenteric and omental adipocytes, but was higher in these two regions when compared to subcutaneous adipocytes. For dobutamine and terbutaline no signi®cant regional differences were found. CONCLUSION: b b3-adrenoceptor action is enhanced and a a2-adrenoceptor action is decreased in both mesenteric and omental adipocytes as compared to subcutaneous adipocytes. However, the two visceral fat depots show no difference in adrenoceptor function. The difference in b b3-and a a2-adrenoceptor function might explain why noradrenaline induced lipolysis is increased in the two visceral fat depots, as compared to the subcutaneous fat depot.
Introduction
The adrenoceptor system plays an important role in the regulation of lipid mobilization. In human adipocytes, catecholamines have either a stimulatory effect on lipolysis via the b1-, b2-and the recently discovered b3-adrenoceptors or an inhibitory effect on lipolysis via the a2-adrenoceptors. 1, 2 It is known that adipose tissue is a heterogeneous organ with variant lipolytic rate in different fat depots (for review, see References 3 and 4). In general, catecholamine-induced lipolysis is increased in visceral adipose tissue as compared to subcutaneous adipose tissue, due to a higher expression of the three different b-adrenoceptor subtypes and a lower expression of the a2-adrenoceptors in visceral fat. As visceral adipose tissue, in contrary to subcutaneous adipose tissue, has a direct access to the portal vein, free fatty acids (FFA) which are released through lipolysis, may be directly delivered to the liver. An excess of FFA can interfere with liver metabolism and induce hypertriglyceridaemia, hyperinsulinaemia and glucose intolerance, disturbances commonly associated with upper-body obesity.
2±4
Visceral adipose tissue is composed of both omental (peripheral portion of omentum majus, outgoing from the transverse colon) and mesenteric (round ligament, surrounding the bowel at the midgut level) adipose tissue. Most studies on regional differences in lipolysis have concentrated on omental versus subcutaneous fat. 4 However, only a few studies have compared lipolysis in mesenteric adipocytes to the other fat depots.
5±7
In the current study, noradrenaline-induced lipolysis in fat cells from mesenteric, omental and subcutaneous adipose tissue of obese subjects, was compared. To further study if possible differences in the noradrenaline-effect among the fat-depots could be linked to variations in b-adrenoceptor subtype function, adipocytes from the three regions were stimulated with selective b1-, b2-and b3-adrenoceptor agonists and the lipolysis concentration-response curves were studied. In addition, the noradrenaline response (b1-, b2-, b3-and a2-adrenoceptor agonist) was compared with the isoprenaline response (only b1-, b2-and b3-adrenoceptor agonist), to get an idea of the a2-adrenoceptor contribution.
Material and methods

Subjects
The main study group consisted of 13 patients who underwent weight reduction surgery with gastric banding because of obesity. None of the subjects was on regular medication, neither did they have a history of recent changes in food or exercise habits. No selection was made for age (range 23±59 y) or gender (four male and nine female). All the subjects were overweight as the body mass index (BMI) ranged from 36±53 kg/m 2 (43 AE 1, mean AE s.e.m.). The subjects fasted overnight, and general anaesthesia was induced at 8.00 h. 8 The adipose tissue specimens (1±2 g) were obtained within 30 min of the incision in the abdominal wall, from the epigastric region of the abdominal wall (subcutaneous tissue); from the major omentum (omental tissue) and from the midgut level (mesenteric tissue).
A second group, which consisted of ten healthy non-obese volunteers who had fasted overnight, was included for methodological investigations. From these subjects a subcutaneous fat biopsy of about 1 g was collected from the paraumbilical region under local anaesthesia. 8 No selection was made for age (range 17±58 y) or gender (®ve male and ®ve female). The BMI ranged from 20±25 kg/m 2 . We have previously shown 8 that the adrenoceptor-regulation of lipolysis in subcutaneous fat cells is not different, when adipocytes obtained from the same subject during local and general anaesthesia are compared. The study was approved by the Ethical Committee of the Karolinska Institute at Huddinge Hospital. All subjects have their informed consent.
Isolation of fat cells and determinations of cell size and number
The adipose tissue samples were immediately transported to the laboratory in saline at 37 C and fat cells were isolated by collagenase treatment as described by Rodbell. 9 Brie¯y, each fat tissue specimen was cut into fragments of approximately 5±10 mg and incubated for 1 h with 0.5 g/l of collagenase in 5 ml Krebs Ringer Phosphate (KRP) buffer (pH 7.4) with 40 g/l of dialyzed bovine serum albumin at 37 C in a shaking bath. The adipocytes were ®ltered twice through a nylon cloth and were subsequently washed three times with a collagenase free buffer. Using direct microscopy, the diameter of 100 adipocytes was determined and from these data, the mean adipocyte diameter and standard deviation were calculated. Assuming that the measured cells are spheres, the mean fat cell volume could be calculated from these values. The fat cell weight was calculated using the density of human fat cell triglyceride (it is assumed that lipids constitute b 95% of a fat cell). The total lipid content in the incubate was measured gravimetrically after organic extraction with heptane, while the number of adipocytes was calculated by dividing the total lipid weight by the mean cell weight, as described previously. 10, 11 Lipolysis Adipocytes (5±10 000 cells/ml) were incubated in duplicate at 37 C in a shaking bath in 0.2 ml KRP buffer (pH 7.4) containing 20 g/l BSA, 1 g/l glucose, 0.1 mg/l ascorbic acid and various concentrations of (anti)lipolytic agents with air as the gas phase. The ligands were added simultaneously at the start of the incubation. The following ligands were added to the adipocytes from the obese subjects of the main study; the non-selective natural catecholamine noradrenaline, which acts on all adrenoceptors present in human adipocytes (for example a2-, b1-, b2-and b3-adrenoceptors), the b1-, b2-and b3-adrenoceptor agonist isoprenaline, the selective b1-adrenoceptor against dobutamine, the selective b2-adrenoceptor agonist terbutaline and the partial selective b3-adrenoceptor and b1-and b2-adrenoceptor agonist CGP 12177. The concentration range used for each agonist was dependent on its lipolytic performance. Overall it ranged from 10 712 to 10 73 mol/l. The following ligands were added to the adipocytes from both the non-obese and the obese subjects in the methodological experiments: noradrenaline (10 75 mol/l) with or without the a2-adrenoceptor antagonist yohimbine (10 74 mol/l) and isoprenaline (10 75 mol/l). The same batches of collagenase and albumin, and the same stock solutions of agonists/antagonist, were used throughout the study. In this incubation system, there is only a minimal in¯uence of contaminating adenosine.
12 Therefore adenosine deaminase was not added to the incubation. After 2 h of incubation, the glycerol concentration which was used as an index of lipolysis, was determined in a cell-free aliquot with a bioluminescence method. 13 Methodological experiments show that basal and adrenoceptor agonistinduced glycerol release is linear for at least 4 h. All agonists caused a concentration dependent stimulation of glycerol release which reached a plateau at the highest agonist concentrations. Concentrationresponse curves for glycerol release were used to determine the lipolytic sensitivity of each agonist, expressed as the pD 2 value (-log mol/l), for example, the negative logarithm of the EC 50 value, which is the concentration of the agonist giving half maximum effect.
14 This was determined by linear regression analysis after log-logit transformation of the ascending part of the concentration-response curve. Maximal lipolytic rates of the agonists were used as an indica-tion of lipolytic responsiveness. The lipolytic rates were corrected for the difference in basal lipolysis between omental, subcutaneous and mesenteric fat tissue, by subtracting the basal values. Furthermore, the intrinsic activity was determined by comparing the maximum effect of the different agonists with the maximum effect of isoprenaline (expressed as percentage of maximum isoprenaline effect). As isoprenaline causes maximal lipolysis due to its b1-, b2-and b3-adrenoceptor properties, the intrinsic activity is an indication of the coupling ef®ciency of the agonists to the b-adrenoceptor effector system.
14 Lipolysis was expressed either as a function of the lipid weight of the incubated adipocytes or per number of cells incubated.
Drugs and chemicals
Bovine serum albumin (fraction V), Clostridium histolyticum collagenase type I, yohimbine and glycerol kinase from Escherichia coli were obtained from Sigma Immunochemicals (St Louis, MO, USA). Noradrenaline and (-)isoprenaline hydrocholoride was obtained from Ha Èssle (Mo Èlndal, Sweden), terbutaline sulphate from Draco (Lund, Sweden), dobutamine hydrochloride from Eli Lilly (Indianapolis, Indiana, USA), CGP 12177 from Ciba Geigy (Basel, Switzerland) and ATP monitoring reagent containing ®re¯y luciferase from LKB Wallac (Turku, Finland).
Statistical analysis
Values are given as the mean AE standard error of the mean (s.e.m.). Analysis of variance (ANOVA, one way and repeated measures) and (post-hoc) paired ttest were used for statistical comparisons.
Results
The clinical data from the obese subjects are shown in Table 1 . In addition to obesity, these subjects displayed characteristics associated with obesity, such as high plasma insulin and serum triglyceride concentrations.
Basal lipolysis and maximum isoprenaline lipolytic effects were measured in mesenteric, omental and subcutaneous adipocytes from these obese subjects, and were related to fat cell size ( Table 2 ). The adipocytes from the three different regions were signi®cantly different in size. Omental adipocytes were smaller than the subcutaneous and mesenteric adipocytes, which did not differ between each other in cell volume. When lipolysis was expressed per gram of lipid, neither basal nor isoprenaline-induced glycerol release differed between the three regions. However, when lipolysis was expressed per cell, signi®cant variations in basal and isoprenalineinduced glycerol release between all the three regions were observed. It is well known that fat cell size markedly in¯uences the values for glycerol release when lipolysis is expressed per cell. 2 It is apparent that there were marked regional variations in fat cell size and basal or maximal lipolysis rates per cell, whereas no site variations were present when lipolysis was expressed per gram of lipid. In order to avoid site differences related to variations in adipocyte size, we have decided to express lipolysis per gram of lipid.
The noradrenaline-and isoprenaline-induced glycerol release from adipocytes of the three different fat depots from the obese subjects are depicted in Figure  1 . Both noradrenaline and isoprenaline stimulated lipolysis in a concentration-dependent fashion. Noradrenaline was signi®cantly more effective (about 50%) in mesenteric or omental adipocytes as compared to subcutaneous adipocytes (repeated measures ANOVA, P`0.05), whereas no signi®cant difference was observed between the two visceral sites. There was no signi®cant difference in the mean concentration-response curves for isoprenaline-induced lipolysis, when the three regions were compared. Figure 2 shows the mean concentration-response curves for the three different selective b-adrenoceptor agonists. They all stimulated glycerol release in a concentration-dependent fashion. The glycerol release from the three regions was almost identical when the adipocytes were stimulated with dobutamine and terbutaline. However, CGP 12177 stimulation resulted in a signi®cantly higher glycerol release (about 50%) from omental or mesenteric adipocytes than from subcutaneous adipocytes (repeated measures ANOVA, P`0.05), whereas there was no signi®cant difference between the two visceral sites.
The fact that some of the concentration-response curves in Figure 2 are not classically sigmoid is due to the curves being constructed from mean values and thereby considerably in¯uenced by variations in leftright position of the individual concentration-response curves. However, the corresponding individual curves were always steep and sigmoid. When the curves are compared with those from our earlier reports, 15 there seems to be a shift to the right with noradrenaline, dobutamine and isoprenaline. It is assumed that this is linked to the obese status of the subjects. Table 3 depicts the pharmacological properties of the adrenoceptor agonists. As regards pD 2 , the sensitivities to noradrenaline and CGP 12177 were higher in mesenteric or omental adipocytes than in subcutaneous adipocytes (paired t-test, P2: 9.0 AE 0.2 (mesenteric), 0.2 AE 0.2 (omental) vs 8.5 AE 0.1 (subcutaneous), P`0.05). This is also illustrated by a rightward shift Dobutamine and terbutaline were full agonists with values for intrinsic activity of b 90% of isoprenaline action, that did not differ between the three fat depots. Noradrenaline and CGP 12177 acted as partial agonists (`85% of isoprenaline action) in the three adipose tissue depots. The intrinsic activity for noradrenaline and CGP 12177 was signi®cantly higher in omental or mesenteric adipocytes than in subcutaneous adipocytes (paired t-test, P`0.05). The responsiveness to noradrenaline was thus about 50% higher in mesenteric or omental adipocytes as compared to subcutaneous adipocytes (paired t-test, P`0.05) and the responsiveness to CGP 12177 was signi®cantly higher (about 40%) in mesenteric adipocytes than in subcutaneous adipocytes (paired t-test, P`0.05). In contrast, responsiveness to isoprenaline (Table 2) , dobutamine and terbutaline stimulation did not differ between any of the three regions.
The observed regional differences in noradrenalineinduced lipolysis could not only be explained by differences in b-adrenoceptor subtype status (investigated using the selective b1-, b2-and b3-adrenoceptor agonists and isoprenaline), but also by differences in antilipolytic a2-adrenoceptor status. Although the latter receptor was not the major focus in this study, some methodological experiments were done to investigate the in¯uence of the a2-adrenoceptor action on the maximal lipolytic effect of noradrenaline. In Table 4 , the effect of a maximum effective concentration (10 74 mol/l) of the a2-adrenoceptor antagonist, yohimbine, on noradrenaline-induced glycerol release (maximum effective hormone concentration 10 75 mol/l) in subcutaneous adipocytes is shown. In subcutaneous adipocytes from 10 non-obese subjects, the noradrenaline-induced glycerol release was nearly 50% less than the isoprenaline-induced glycerol release. When yohimbine was added together with noradrenaline, the glycerol release as compared with noradrenaline alone, increased signi®cantly (paired t-test, P`0.01) and almost reached the level of isoprenaline. In subcutaneous adipocytes from 3 sc subcutaneous and me mesenteric fat tissue were compared using a paired t-test. The P-values were corrected according to Bonferroni. NS not signi®cant.
Catecholamine-induced adipocyte lipolysis
V Van Harmelen et al obese subjects, nearly the same results were obtained as in the non-obese subjects (Table 4) .
Discussion
This study intended to compare noradrenalinemediated lipolysis in fat cells with the mesenteric, omental and subcutaneous tissue regions from obese subjects. Furthermore, the contribution of the various adrenoceptor subtypes (focusing on the b-adrenoceptors) to the lipolysis in the different adipose tissue regions was investigated, to clarify any differences in noradrenaline-response. The current data show that omental adipocytes were smaller than both mesenteric and subcutaneous adipocytes. This is in agreement with some previously performed studies, 16, 17 whereas others have not found any difference in cell size between the three adipose tissue regions in obese subjects. 6 The mesenteric and subcutaneous adipocytes did not differ signi®cantly in cell size. This is in disagreement with the study of Vikman and Ohisalo, 17 in which it was found that mesenteric adipocytes were larger than subcutaneous adipocytes. However, it is unclear from the Vikman and Ohisala 17 report whether the subjects were obese. As it appears that regional differences in adipocyte size are dependent upon body weight, 6 ,7 the selection of patient material could at least partly explain the discrepancy.
In the present study, lipolysis was expressed per unit weight of fat cells rather than per cell for several reasons. First, both basal and maximal rates of lipolysis differed between the regions in a way that could be related to site variations in fat cell size. Second, we considered it to be more relevant, in physiological terms, to compare the same amount of fat (for example, weight) rather than the same number of adipocytes (differing in total weight and volume). However, it should be stressed that the values of adrenoceptor sensitivity (pD 2 ) and intrinsic activity are the same when expressed per gram of lipid or per cell. In other words, the latter basic pharmacological receptor properties are not cell size dependent.
Basal and isoprenaline-induced lipolysis did not display regional variations when expressed per lipid weight. Furthermore, noradrenaline stimulated lipolysis seemed to be in the same order of magnitude in omental and mesenteric adipocytes, whereas the subcutaneous adipocyte lipolytic response to noradrenaline was signi®cantly lower. Noradrenaline sensitivity, intrinsic activity and responsiveness were all signi®-cantly higher in the visceral fat regions as compared to the subcutaneous fat region.
The increased lipolytic sensitivity to noradrenaline in the visceral adipocytes indicates a different function of one or more of the adrenoceptor subtypes in these adipocytes as compared to the subcutaneous ones. Isoprenaline sensitivity (for example, pD 2 ) was, like noradrenaline, higher (about ®ve times) in the visceral than in the subcutaneous fat cells. These data strongly indicate that part of the regional difference in noradrenaline-induced lipolysis was due to site variations in one or several of the b-adrenoceptor subtypes.
It seems that the higher noradrenaline-induced lipolytic activity in the two visceral fat depots might partly be explained by the b3-adrenoceptor function, but not by the b1-and b2-adrenoceptor function. Stimulation with dobutamine (b1-adrenoceptor agonist) and terbutaline (b2-adrenoceptor agonist) did not reveal any differences between the three adipose tissue regions, while lipolysis stimulation with CGP 12177 (b3-adrenoceptor agonist) resulted in signi®-cantly higher sensitivity and intrinsic activity in the visceral adipocytes as compared to the subcutaneous adipocytes.
As noradrenaline also stimulates a2-adrenoceptors, it is possible that differences in a2-adrenoceptor function might contribute to the observed regional differences in noradrenaline-induced lipolysis as well. Noradrenaline was a partial agonist in adipocytes of all three depots. Methodological experiments clearly demonstrated that this partial antagonism above all was due to the antipolytic a2-adrenoceptor component of the hormone. Addition of the selective a2-adrenoceptor antagonist yohimbine to subcutaneous fat cells (where the partial agonism of noradrenaline was most apparent) almost completely restored the lipolytic agonism of noradrenaline in relation to isoprenaline (which lacks a2-adrenoceptor properties). It was evident that the intrinsic activity of noradrenaline, in relation to isoprenaline, was much higher in the two visceral adipocyte types than in the subcutaneous adipocytes. This suggests that the a2-adrenoceptor contribution of noradrenaline is greater in the subcutaneous than in the visceral adipocytes. In order to fully elucidate the importance of the a2-adrenoceptor for lipolysis in the three regions, extensive experiments are needed, using selective a2-adrenoceptor agonists and experiments with noradrenaline together with b-adrenoceptor antagonists. Unfortunately, the amount of adipose tissue available was too small for these additional experiments.
Adrenoceptor-induced lipolysis in mesenteric, omental and subcutaneous fat depots has been compared simultaneously only in a few other studies. Rebuffe Â-Scrive et al 5, 6 found no major regional differences using non-selective agonists (isoprenaline and noradrenaline) in obese subjects, 6 whereas in non-obese subjects they found striking differences between the visceral and the subcutaneous fat depots. 5 Furthermore, Maurie Áge et al 7 investigated adipocytes from obese premenopausal women using isoprenaline, procaterol (b2-adrenoceptor agonist), BRL 37344 (b3-adrenoceptor agonist) and UK 14304 (a2-adrenoceptor agonist). They observed a higher b-adrenergic sensitivity in the omental adipose tissue as compared to both the subcutaneous and the mesenteric tissue and a lack of regional a2-andrenoceptor response variation. 7 Possible reasons for the discrepancies between the former reports and the present study could be differences in composition of the subject group, such as number of subjects, distribution of men/women, age range, body constitution and body weight. Besides, different lipolysis measurement methods have been used. In our study the adipocytes were incubated under diluted conditions, which is thought to prevent effects of accumulating potential active antilipolytic metabolites. Rebuffe Â-Scrive et al, 5, 6 however, incubated the fat cells under dense conditions. Finally, results may vary due to use of different selective b-adrenoceptor agonists. Maurie Áge et al 7 used BRL 37344, which is not an ideal b3-adrenoceptor agonist in man, because of its b1-and b2-adrenoceptor agonist properties. 18, 19 In the current study CGP 12177 was used, which is a selective b3-adrenoceptor agonist and b1-and b2-antagonist in human fat cells.
In contrast to b1-and b2-adrenoceptors, the b3-adrenoceptor is dif®cult to study in human adipocytes (for review, see Reference 2) . Some of the puzzling questions about b3-adrenoceptors in human fat cells have recently been addressed. 20, 21 However, it is possible that methodological factors explain why a b3-adrenoceptor response is hard to detect in some human fat cell incubation systems. 22 On the other hand, it is possible to detect signi®cant and reproducible b3-adrenoceptor mediated lipolysis using our incubation system. We have clearly demonstrated that CGP 12177 acts on a different lipolytic receptor than dobutamine and terbutaline in subcutaneous and omental adipocytes. 23 A marked lipolytic response of noradrenaline and adrenaline is maintained during the selective b1-and b2-adrenoceptor blockade. 24 The lipolytic potency for isoprenaline, noradrenaline and adrenaline during the selective blockade of b1-, b2-and a2-adrenoceptors, is in agreement with that for a b3-adrenoceptor. 24 Finally, the interaction between adrenoceptor agonists and antagonists on the one hand and the b3-adrenoceptor on the other hand is almost identical in human fat cells as compared to mouse 3T3-L1 adipocytes.
The nature of the increased b3-adrenoceptor function in the mesenteric and omental adipocytes as compared to the subcutaneous adipocytes still remains unclear. However, it could be speculated that the increased intrinsic activity of CGP 12177 in the visceral adipose tissue is due to an increased coupling of the b3-adrenoceptor to the effector system. 25 Also, the increased sensitivity suggests an increase in number and/or coupling of b3-adrenoceptors in the mesenteric and omental adipocytes, as a change in sensitivity is a re¯ection of an alteration in these two properties of the receptor.
14 However, it was not possible to investigate these aspects of the b3-adrenoceptor in detail. So far, there are no methods available to quantify the b3-adrenoceptor protein or mRNA (in human adipose tissue), as discussed in detail. 20, 25 Finally, it has to be stressed that the a2-adrenoceptor function in non-obese subjects may be different from that in obese subjects. It was not possible to perform this type of study on non-obese subjects, as it is in most cases very dif®cult to obtain mesenteric fat in suf®cient amounts. Also, we do not know how the present data relate to lipolysis in vivo. For ethical reasons it is not possible to determine in vivo lipolysis in the visceral fat depots.
In conclusion, this study shows that there is apparently no difference in the lipolytic effect of catecholamines in omental and mesenteric adipocytes from obese subjects. However, the catecholamine induced lipolytic response of adipocytes from these regions is higher than that of the subcutaneous adipocytes. This regional difference seems at least in part to be due to an enhanced b3-adrenoceptor action and a decreased a2-adrenoceptor action in the mesenteric and omental adipocytes as compared to the subcutaneous adipocytes. Additional regional variations in lipolysis which are related to fat cell size and number, might exist as well.
